Li Y, Zhang N, Zhang L, et al. - In this study that included two independent cohorts with 319 patients, researchers investigated if functional HSPH1 SNP (single-nucleotide polymorphism) can influence gene expression and consequently prognosis of non-small-cell lung cancer (NSCLC) patients managed with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). In both cohorts, a significant link between promoter rs2280059 polymorphism and patient survival was evident. A higher ability to drive HSPH1 promoter activities was demonstrated by rs2280059 G allele, as per in vitro and in vivo assays. A significant increase in the antineoplastic impacts of gefitinib on NSCLC cells was induced by silencing HSPH1. Overall, HSPH1 has potential clinical implications, which may afford better understanding and a better ability to assess outcomes of EGFR-TKI therapy.